Skip to Content

Insulin glargine / lixisenatide Pregnancy and Breastfeeding Warnings

Insulin glargine / lixisenatide is also known as: Soliqua

Medically reviewed by Last updated on Mar 11, 2019.

Insulin glargine / lixisenatide Pregnancy Warnings

Benefit should outweigh risk

US FDA pregnancy category: Not Assigned

Risk Summary: The limited data with this drug in pregnant women is not sufficient to inform a drug-associated risk of major birth defects and miscarriage; animal studies suggest there may be a risk to the fetus from exposure to lixisenatide.

Comment: There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy; insulin therapy is considered a drug of choice during pregnancy.

Studies in pregnant rats and rabbits at doses of 1 and 6 times the recommended human dose, respectively, were associated with visceral closure and skeletal defects at exposures that decreased maternal food intake and weight gain during gestation. Published studies with insulin glargine have not reported a clear association with major birth defects or miscarriage risk. Poorly controlled diabetes in pregnancy increases the maternal risks for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery and delivery complications; and fetal risks for major birth defects, still birth, and macrosomia related morbidity. There are no controlled data in human pregnancy.

Patients with diabetes or a history of gestational diabetes should maintain good metabolic control before conception and during pregnancy. Insulin requirements may decrease during the first trimester; generally, increase during the second and third trimesters, and rapidly decline after delivery. Careful monitoring of glucose control is essential.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Insulin glargine / lixisenatide Breastfeeding Warnings

Benefit should outweigh risk

Excreted into human milk: Insulin glargine (yes); Lixisenatide (unknown)
Excreted into animal milk: Yes (lixisenatide)

-There is no information on the effects of this combination product on the breastfed infant, or the effects on milk production.
-Insulin glargine is considered compatible with breastfeeding; women who are breastfeeding may require adjustments of their insulin dose.

Exogenous insulins, including insulin glargine appear to be excreted into breast milk. Insulin is a protein that is inactivated if taken by mouth. If absorbed, it would be destroyed in the digestive tract of the infant. There is no information on the presence of lixisenatide in human milk. In lactating rats, milk transfer of lixisenatide and its metabolites were low (9.4%) and levels of unchanged drug in the gastric contents of weaning offspring was negligible (0.01%).

See references

References for pregnancy information

  1. "Product Information. Soliqua 100/33 (insulin glargine-lixisenatide)." sanofi-aventis, Bridgewater, NJ.

References for breastfeeding information

  1. "Product Information. Soliqua 100/33 (insulin glargine-lixisenatide)." sanofi-aventis, Bridgewater, NJ.
  2. "Product Information. Lantus (insulin glargine)" Aventis Pharmaceuticals, Swiftwater, PA.
  3. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.